| abstract |
The present disclosure provides isolated monoclonal antibodies that specifically bind with high affinity to human natural killer cell inhibitory receptor group 2A (NKG2A) protein and exhibit therapeutically desirable functional properties, such as for the treatment of cancer (e.g., eg, humanized and human monoclonal antibodies) or antigen-binding fragments thereof. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising an anti-NKG2A antibody of the invention are also provided. Further provided are nucleic acid molecules encoding the antibody, expression vectors, host cells, and methods of treating, eg, cancer, using the antibody. An anti-NKG2A antibody of the disclosure is co-administered with at least one additional agent, such as another antibody (eg, an anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibody). -administered combination therapies are also provided. |